Profile data is unavailable for this security.
About the company
Terns Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity. Its pipeline includes three clinical-stage development programs: TERN-701, TERN-601 and TERN-501. TERN-701 is its oral, potent, allosteric BCR-ABL tyrosine kinase inhibitors (TKI) specifically targeting the ABL myristoyl pocket for CML, a form of cancer that begins in the bone marrow and leads to the growth of leukemic cells. TERN-601 is a small-molecule glucagon-like peptide-1 receptor (GLP-1R) agonist that is intended to be orally administered for obesity and other metabolic diseases. TERN-501 is a thyroid hormone receptor beta (THR-b) agonist with high metabolic stability and liver distribution. It is also focused on developing the TERN-800 series of small-molecule glucose-dependent insulinotropic polypeptide receptor (GIPR) modulators for obesity.
- Revenue in USD (TTM)0.00
- Net income in USD-95.90m
- Incorporated2020
- Employees66.00
- LocationTerns Pharmaceuticals Inc1065 East Hillsdale Blvd.Suite 100, Suite 100FOSTER CITY 94404United StatesUSA
- Phone+1 (650) 525-5535
- Fax+1 (650) 275-4395
- Websitehttps://ternspharma.com/
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Olema Pharmaceuticals Inc | 0.00 | -109.63m | 781.11m | 80.00 | -- | 3.44 | -- | -- | -2.06 | -2.06 | 0.00 | 3.97 | 0.00 | -- | -- | 0.00 | -50.73 | -30.06 | -56.10 | -31.40 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 7.76 | -- | -- | -- |
ORIC Pharmaceuticals Inc | 0.00 | -110.78m | 793.60m | 107.00 | -- | 2.52 | -- | -- | -1.76 | -1.76 | 0.00 | 4.47 | 0.00 | -- | -- | 0.00 | -35.69 | -33.92 | -37.77 | -35.77 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -12.99 | -- | 10.09 | -- |
Erasca Inc | 0.00 | -158.28m | 816.44m | 126.00 | -- | 1.75 | -- | -- | -0.9207 | -0.9207 | 0.00 | 1.65 | 0.00 | -- | -- | 0.00 | -32.76 | -- | -34.48 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 48.50 | -- | -- | -- |
Dianthus Therapeutics Inc | 4.12m | -56.68m | 821.92m | 53.00 | -- | 2.29 | -- | 199.59 | -5.54 | -5.54 | 0.2092 | 12.20 | 0.0184 | -- | -- | 77,698.11 | -25.33 | -41.40 | -26.15 | -44.70 | -- | -- | -1,376.42 | -12,132.27 | -- | -- | 0.00 | -- | -- | -- | 43.04 | -- | -57.21 | -- |
Arrivent Biopharma Inc | 0.00 | -74.89m | 833.27m | 40.00 | -- | 2.80 | -- | -- | -2.46 | -2.46 | 0.00 | 8.85 | 0.00 | -- | -- | 0.00 | -29.50 | -- | -31.02 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -87.86 | -- | -- | -- |
Terns Pharmaceuticals Inc | 0.00 | -95.90m | 845.68m | 66.00 | -- | 3.22 | -- | -- | -1.31 | -1.31 | 0.00 | 3.11 | 0.00 | -- | -- | 0.00 | -36.84 | -41.34 | -38.72 | -45.70 | -- | -- | -- | -31,010.30 | -- | -- | 0.00 | -- | -- | -- | -49.49 | -- | -26.60 | -- |
Silence Therapeutics plc | 23.85m | -53.42m | 852.48m | 115.00 | -- | 6.18 | -- | 35.75 | -0.4294 | -0.4294 | 0.1905 | 1.07 | 0.1273 | -- | 2.56 | 207,357.10 | -28.51 | -43.60 | -32.89 | -54.91 | 56.40 | -- | -224.01 | -287.30 | -- | -- | 0.0016 | -- | 44.99 | -- | -6.86 | -- | 156.10 | -- |
89bio Inc | 0.00 | -174.61m | 867.40m | 70.00 | -- | 1.67 | -- | -- | -1.97 | -1.97 | 0.00 | 4.91 | 0.00 | -- | -- | 0.00 | -32.50 | -45.50 | -34.68 | -49.31 | -- | -- | -- | -- | -- | -- | 0.0465 | -- | -- | -- | -39.37 | -- | -36.58 | -- |
Oruka Therapeutics Inc | 0.00 | -7.20m | 874.96m | 4.00 | -- | 0.9278 | -- | -- | -5.97 | -5.97 | 0.00 | 26.94 | 0.00 | -- | -- | 0.00 | -19.22 | -27.78 | -19.99 | -29.38 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 46.21 | -- | -- | -- |
Applied Therapeutics Inc | -333.00k | -161.09m | 884.32m | 31.00 | -- | 12.22 | -- | -- | -1.52 | -1.52 | -0.0029 | 0.6303 | -0.0039 | -- | -- | -13,320.00 | -187.94 | -140.37 | -467.74 | -240.93 | -- | -- | -- | -4,476.42 | -- | -- | 0.00 | -- | -- | -- | -45.15 | -- | -- | -- |
Tango Therapeutics Inc | 42.51m | -116.49m | 889.30m | 140.00 | -- | 3.59 | -- | 20.92 | -1.11 | -1.11 | 0.4068 | 2.31 | 0.1118 | -- | -- | 303,635.70 | -30.62 | -- | -35.13 | -- | -- | -- | -274.04 | -- | -- | -- | 0.00 | -- | 46.93 | -- | 5.95 | -- | -- | -- |
Perspective Therapeutics Inc | -1.87m | -49.02m | 892.07m | 116.00 | -- | 2.62 | -- | -- | -1.39 | -1.75 | -0.0437 | 5.06 | -0.0074 | -- | -- | -16,086.21 | -19.37 | -- | -20.14 | -- | -- | -- | -- | -- | -- | -- | 0.005 | -- | -- | -- | -- | -- | -- | -- |
MiMedx Group Inc | 340.46m | 89.67m | 899.94m | 895.00 | 12.27 | 5.35 | 9.17 | 2.64 | 0.4996 | 0.4622 | 2.08 | 1.15 | 1.67 | 2.70 | 6.69 | 380,402.30 | 48.16 | -4.14 | 60.79 | -5.90 | 83.41 | 83.61 | 28.76 | -2.70 | 3.22 | 13.06 | 0.1028 | -- | 20.03 | -2.19 | 310.29 | -- | -26.47 | -- |
Immunome Inc | 10.78m | -262.59m | 900.22m | 55.00 | -- | 3.54 | -- | 83.48 | -5.64 | -5.64 | 0.2591 | 4.23 | 0.0639 | -- | -- | 196,072.70 | -155.54 | -94.54 | -193.54 | -112.66 | -- | -- | -2,435.02 | -1,403.15 | -- | -- | 0.00 | -- | -- | -- | -184.68 | -- | 29.52 | -- |
Holder | Shares | % Held |
---|---|---|
Deep Track Capital LPas of 31 Mar 2024 | 6.10m | 9.43% |
Millennium Management LLCas of 31 Mar 2024 | 3.43m | 5.31% |
Soleus Capital Management LP (Investment Management)as of 06 Jun 2024 | 3.34m | 5.17% |
Citadel Advisors LLCas of 10 Jul 2024 | 3.29m | 5.09% |
BlackRock Fund Advisorsas of 31 Mar 2024 | 2.96m | 4.57% |
Fidelity Management & Research Co. LLCas of 31 Mar 2024 | 2.76m | 4.27% |
Franklin Advisers, Inc.as of 31 Mar 2024 | 2.38m | 3.68% |
Point72 Asset Management LPas of 31 Mar 2024 | 2.22m | 3.43% |
The Vanguard Group, Inc.as of 31 Mar 2024 | 2.11m | 3.26% |
Fairmount Funds Management LLCas of 31 Mar 2024 | 2.04m | 3.15% |